D.E. Shaw & Co
TLSI icon

D.E. Shaw & Co’s TriSalus Life Sciences TLSI Stock Holding History

D.E. Shaw & Co’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-457,874
Closed -$4.55M – 5126
2022
Q3 		$4.55M Buy
457,874
+60,368
+15% +$597K 0.01% 2206
2022
Q2 		$3.91M Buy
397,506
+204,867
+106% +$2.01M ﹤0.01% 2426
2022
Q1 		$1.89M Buy
192,639
+74,339
+63% +$734K ﹤0.01% 3356
2021
Q4 		$1.17M Hold
118,300
– – ﹤0.01% 3800
2021
Q3 		$1.18M Buy
+118,300
New +$1.16M ﹤0.01% 3478

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

D.E. Shaw & Co's TLSI Position: Q4 2022 in Review

D.E. Shaw & Co sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 457,874 shares — an estimated $4.55M sold.

D.E. Shaw & Co first reported a position in TLSI in Q3 2021 and held it in 5 quarters. The position peaked at $4.55M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • D.E. Shaw & Co reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 457,874 TriSalus Life Sciences shares in Q4 2022, an estimated $4.55M.
  • D.E. Shaw & Co first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's TriSalus Life Sciences position peaked at $4.55M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.